Cargando…

Efficacy of front‐line immunochemotherapy for transplant‐ineligible mantle cell lymphoma: A network meta‐analysis of randomized controlled trials

BACKGROUND: There is no standard first‐line immunochemotherapy regimen for transplant‐ineligible patients with mantle cell lymphoma (MCL) currently, and the efficacy of various treatment remains unclear. METHODS: We conducted a Bayesian network meta‐analysis (NMA) of all eligible randomized controll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jing, Caixia, Zhao, Ailin, Wang, Jinjin, Niu, Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	REVIEW
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417079/ https://www.ncbi.nlm.nih.gov/pubmed/37264757 http://dx.doi.org/10.1002/cam4.6183

Ejemplares similares

Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma
por: Ratnasingam, Sumita, et al.
Publicado: (2019)

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials
por: Wang, Yucai, et al.
Publicado: (2022)

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma
por: Jin, Jie, et al.
Publicado: (2018)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Efficacy of ESHAP Regimen in Transplant Ineligible Patients With Relapsed/Refractory T-Cell Lymphoma
por: Norasetthada, Lalita, et al.
Publicado: (2018)

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
por: Avet-Loiseau, Herve, et al.
Publicado: (2018)

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy
por: Ye, Haige, et al.
Publicado: (2018)

Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
por: Rodríguez-Sevilla, Juan Jose, et al.
Publicado: (2022)

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy
por: Jamois, Candice, et al.
Publicado: (2019)

Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials
por: Wang, Jinjin, et al.
Publicado: (2022)

S313: HEALTH ECONOMIC EVALUATION OF THIRD-LINE INTERVENTIONS FOR TRANSPLANT-INELIGIBLE RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN GERMANY
por: Sophie Kurte, Melina, et al.
Publicado: (2023)

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up
por: Romejko-Jarosinska, Joanna, et al.
Publicado: (2022)

Stem cell transplant for mantle cell lymphoma in Taiwan
por: Wang, Yu-Hung, et al.
Publicado: (2022)

Campylobacter fetus spondylodiscitis during immunochemotherapy for non-Hodgkin's lymphoma
por: Cunha, Jéssica Santos, et al.
Publicado: (2021)

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
por: Runge, John S., et al.
Publicado: (2020)

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
por: Al-Sarayfi, Diana, et al.
Publicado: (2022)

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
por: Houot, Roch, et al.
Publicado: (2023)

Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients
por: Douglas, Melanie
Publicado: (2020)

Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan
por: Cheng, Chih-Ning, et al.
Publicado: (2021)

Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas
por: Yi, Jun Ho
Publicado: (2021)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2020)

Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma
por: Durie, Brian G. M., et al.
Publicado: (2020)

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma
por: Paszkiewicz‐Kozik, Ewa, et al.
Publicado: (2022)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
por: Herold, Michael, et al.
Publicado: (2022)

How I manage frontline transplant-ineligible multiple myeloma
por: Derudas, Daniele, et al.
Publicado: (2020)

How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis
por: Lyu, Wen-Wen, et al.
Publicado: (2016)

Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wang, Jinjin, et al.
Publicado: (2020)

First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: A Systematic Analysis and Treatment Recommendation
por: Liu, Hailing, et al.
Publicado: (2022)

Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
por: Houot, Roch, et al.
Publicado: (2023)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
por: Rodríguez, Marta, et al.
Publicado: (2022)

Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis
por: Xie, Chunhong, et al.
Publicado: (2022)

Mantle Cell Lymphoma Presenting as Diarrhea in a Liver Transplant Recipient
por: Ahmed, Abdelwahab, et al.
Publicado: (2021)

Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: a systematic review and meta-analysis on prospective clinical trials
por: Yang, Peipei, et al.
Publicado: (2023)

S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
por: Houot, Roch, et al.
Publicado: (2023)

Smoldering mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2017)

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
por: Puig, Noemi, et al.
Publicado: (2021)

Current trends of anticancer immunochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients
por: Djebbari, Faouzi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jjtudvufn38nnil1o7781kh4a6